Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention and Treatment

Urology, 04/06/2012

The observation that males born with 5α–R 2 deficiency have never been reported to develop prostate cancer stimulated interest in development of 5 α–R inhibitors. Thus far, 2 5α–R inhibitors are approved for clinical use.

Print Article Summary Cat 2 CME Report